Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

STADA

- PMLiVE

Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment

If approved, this would be the first C5 complement inhibitor available for this rare kidney disease

- PMLiVE

Game On: Medscape Education Golfs for a Cause

Medscape Education is proud to stand alongside the National Kidney Foundation (NKF) as a sponsor of one of the nation’s most impactful charity events benefiting patients living with kidney disease,...

Medscape Education

- PMLiVE

FDA approves Apellis’ Empaveli for two rare kidney diseases

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

- PMLiVE

Otsuka shares promising phase 3 results for sibeprenlimab in rare kidney disease IgAN

The trial will continue to evaluate change in kidney function over two years

- PMLiVE

Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy

Almost 13 out of every million people in the US are diagnosed with IgAN each year

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

- PMLiVE

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links